Physiologic basis for hormonal theapy in carcinoma of the prostate.
D000315:Adrenalectomy; D000726:Androgen Antagonists; D000728:Androgens / Q000096:biosynthesis / Q000378:metabolism; D000818:Animals; D002369:Castration; D055598:Chemical Phenomena; D002621:Chemistry; D002715:Chlormadinone Acetate / Q000627:therapeutic use; D003534:Cyproterone / Q000627:therapeutic use; D003864:Depression, Chemical; D013196:Dihydrotestosterone / Q000378:metabolism; D004967:Estrogens / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D007016:Hypophysectomy; D007986:Luteinizing Hormone / Q000378:metabolism; D008297:Male; D011467:Prostate / Q000254:growth & development / Q000502:physiology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013739:Testosterone / Q000378:metabolism / Q000502:physiology
D000726:Androgen Antagonists; D000728:Androgens; D004967:Estrogens; D006728:Hormones; D013196:Dihydrotestosterone; D002715:Chlormadinone Acetate; D013739:Testosterone; D007986:Luteinizing Hormone; D003534:Cyproterone